The correction relates to around three million sensors used in Abbott’s FreeStyle Libre 3 and Libre 3 Plus CGMs in the US.
Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...